| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00006-3029-02 | 00006-3029 | Pembrolizumab | Keytruda | 50.0 mg/2mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 4, 2014 | Dec 21, 2015 | In Use |
| 70377-0053-12 | 70377-0053 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 59651-0347-01 | 59651-0347 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 83257-0003-01 | 83257-0003 | Trastuzumab-dkst, Trastuzumab | OGIVRI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
| 55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
| 79952-0110-01 | 79952-0110 | loncastuximab tesirine | ZYNLONTA | 10.0 mg/2mL | Immunotherapy | Drug Antibody Conjugate | CD19 | Intravenous | Apr 30, 2021 | In Use | |
| 75987-0111-11 | 75987-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | In Use | |
| 00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
| 55566-1050-01 | 55566-1050 | Nadofaragene firadenovec-vncg | ADSTILADRIN | 300000000000.0 {VP}/mL | Immunotherapy | Gene Therapy | IFN⍺2b | Intravesical | Jul 1, 2023 | In Use | |
| 68727-0950-02 | 68727-0950 | Zanidatamab-hrii | ZIIHERA | 50.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2 | Intravenous | Nov 20, 2024 | In Use | |
| 59572-0205-17 | 59572-0205 | Thalidomide | Thalomid | 50.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Dec 1, 2010 | In Use | |
| 47781-0485-28 | 47781-0485 | Lenalidomide | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use | |
| 00480-1244-21 | 00480-1244 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use | |
| 60505-4533-01 | 60505-4533 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | Mar 8, 2023 | In Use |
| 72187-0401-01 | 72187-0401 | Tagraxofusp | Elzonris | 1000.0 ug/mL | Immunotherapy | Fusion Protein | IL3/ CD123 | Intravenous | Jan 18, 2019 | In Use | |
| 72606-0011-01 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
| 45802-0076-00 | 45802-0076 | Imiquimod | Imiquimod | 50.0 mg/1000mg | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Apr 20, 2010 | Aug 1, 2013 | No Longer Used |
| 70377-0051-12 | 70377-0051 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
| 00085-1312-02 | 00085-1312 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Nov 20, 2013 | No Longer Used | ||
| 61755-0008-01 | 61755-0008 | cemiplimab-rwlc | LIBTAYO | 50.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 28, 2018 | In Use | |
| 00085-1242-01 | 00085-1242 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Dec 4, 2010 | No Longer Used | ||
| 55513-0059-01 | 55513-0059 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 1.0 mg/1 | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | May 16, 2024 | In Use | |
| 59572-0425-00 | 59572-0425 | Lenalidomide | Revlimid | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jul 7, 2006 | In Use | |
| 50242-0918-01 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | In Use | |
| 45802-0368-62 | 45802-0368 | Imiquimod | Imiquimod | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Nov 9, 2010 | In Use |
Found 11888 results — Export these results
Home